Physician profile
David H Freeman
NPI 1578582383
$1,391.51
in general payments reported to CMS, 2019-2025
13 companies · $479 in 2025
The $479 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $75.98 · 2022: $141 · 2023: $371 · 2024: $88.94 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $316.54 | 2019-2023 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $224.25 | 2022-2024 | Cequa |
| Biotissue Holdings INC. | $164.64 | 2025 | |
| Bausch & Lomb Americas INC. | $116.25 | 2025 | Infuse |
| Oyster Point Pharma, INC. | $103.75 | 2023 | Tyrvaya |
| Dompe US, INC. | $101.38 | 2025 | Oxervate |
| Alcon Vision LLC | $96.41 | 2025 | Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $61.85 | 2023 | |
| Optos, INC. | $61.28 | 2019 | |
| Aerie Pharmaceuticals, INC. | $57.48 | 2019 | |
| Maculogix, INC. | $48.84 | 2020 | |
| Sight Sciences, INC. | $22.17 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $16.67 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.